Cambridge, Mass. — Sensorion has completed a 50-for-1 reverse share split, reducing the number of shares outstanding while increasing the par value of each share.
The clinical-stage biotechnology company, which develops therapies for hearing loss disorders, said every 50 existing shares with a par value of €0.10 were exchanged for one new share with a par value of €5.
The reverse share split became effective Sept. 15, 2026, following a decision by the company’s Chief Executive Officer on July 27 under authority granted by the Board of Directors and shareholders.
Before the consolidation, Sensorion had 515,648,600 shares outstanding with a par value of €0.10 each. Following the transaction, the company has 10,312,972 shares with a par value of €5 each.
Sensorion waived its right to participate in the consolidation for four treasury shares so the 50-for-1 exchange ratio could be applied to a whole number of shares. Those four shares were canceled upon completion of the transaction.
The new shares began trading Sept. 15 on Euronext Growth Paris under ISIN code FR001401A9Z0.
Shareholders whose holdings were already multiples of 50 did not need to take any action, as their shares were automatically consolidated by their financial intermediaries.
Shareholders with fractional entitlements will receive compensation through their financial intermediary or Uptevia. Compensation for directly registered shares will be paid by Uptevia, while holders of administered registered or bearer shares will receive payment through their account-holding financial intermediary.
The company said compensation for fractional rights is expected to take place between Sept. 17 and Oct. 17, 2026.
Sensorion said it will publish a subsequent notice detailing adjustments to rights or securities that provide access to the company’s capital.
